Avalo Therapeutics, Inc. AVTX
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- -62.83%
- 1 year
- -61.63%
- Market cap
- 390.31M
- Revenue (ttm)
- 59.00K
- EPS (ttm)
- -2.26
- Shares out
- 53.63M
- Forward P/E
- -7.19
- YTD return
- -62.83%
- 1-year return
- -61.63%
- 50-day average
- 19.11
- 200-day average
- 16.92
- Volume
- 710.44K
- Avg volume
- 1.79M
- Open
- 6.73
- Previous close
- 6.70
- Day's range
- 6.53 – 6.87
- 52-week range
- 6.53 – 24.27
- Beta
- 0.79
- Analysts
- Strong Buy
- Price target
- 44.08 (+553.1%)
Key statistics
- Enterprise value
- 631.27M
- Price / sales
- 17916.05
- Price / book
- 2.32
- Free cash flow
- -23.27M
- Total cash
- 400.28M
- Total debt
- 242.00K
- Return on equity
- -36.27%
- Short % of float
- 24.45%
Fundamental scorecard
7 of 25 checks passed on AVTX’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.56337 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.58273 | -0.83 | -0.25 | -42.43% |
| May 13, 2026 | Mar 31, 2026 | -1.00 | -0.98 | +0.02 | +2.00% |
| Mar 23, 2026 | Dec 31, 2025 | -1.54 | -0.74 | +0.80 | +51.95% |
| Nov 6, 2025 | Sep 30, 2025 | -1.67 | -2.19 | -0.52 | -31.14% |
| Aug 7, 2025 | Jun 30, 2025 | -1.43 | -1.92 | -0.49 | -34.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | main | Buy | Buy |
| Aug 7, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 6, 2026 | Leerink Partners | init | — | Outperform |
| Jun 16, 2026 | BTIG | reit | Buy | Buy |
| Jun 12, 2026 | B of A Securities | init | — | Buy |
| May 14, 2026 | Citizens | main | Market Outperform | Market Outperform |
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avalotx.com
News
Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20
Avalo Therapeutics Q3 EPS $(0.34) Beats $(0.61) Estimate
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22
BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10
Your note
Sign in to keep a note on AVTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALMENOFF JUNE SHERIE | Director | Conversion of Exercise of derivative security | Mar 27, 2025 | 4,167 |
| DOYLE MITTIE | Officer | Sale | Aug 27, 2026 | 51,776 |
| GOLDMAN JONATHAN | Director | Conversion of Exercise of derivative security | Mar 26, 2026 | 3,166 |
| KANTOFF AARON | Director | Conversion of Exercise of derivative security | Mar 26, 2026 | 6,333 |
| KAPLAN GILLA | Director | Conversion of Exercise of derivative security | Mar 26, 2026 | 6,333 |
| NEIL GARRY A. M.D. | Chief Executive Officer | Stock Award(Grant) | May 20, 2026 | 190,314 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 9.51% | 5,100,216 | 100.53M | Jun 29, 2026 |
| Blackrock Inc. | 8.14% | 4,365,553 | 86.05M | Jun 29, 2026 |
| Deep Track Capital, Lp | 6.73% | 3,610,000 | 71.15M | Jun 29, 2026 |
| Caligan Partners, LP | 5.90% | 3,163,866 | 62.36M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.63% | 3,017,120 | 59.47M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 5.41% | 2,900,000 | 57.16M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.78% | 2,029,492 | 40.00M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.12% | 1,675,498 | 33.02M | Jun 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 2.25% | 1,208,900 | 23.83M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.04% | 1,093,326 | 21.55M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund | 1.33% | 715,700 | 14.11M | Jun 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.19% | 639,700 | 12.61M | Jul 30, 2026 |
